At a Glance
PureTech Health operates a unique hybrid model that bridges venture capital and pharmaceutical development, functioning as both a biotech company and venture creator. Founded in 2005, the firm identifies promising scientific research and transforms it into clinical-stage therapeutics companies. Unlike traditional VCs, PureTech takes an active role in founding and incubating companies, providing not just capital but also scientific expertise, regulatory guidance, and operational support throughout the drug development process.
The company's approach involves identifying breakthrough research from leading academic institutions and research centers, then building dedicated companies around these innovations with experienced management teams and world-class scientific advisors. PureTech's portfolio spans multiple therapeutic areas including neuroscience, immunology, and digital therapeutics. Their most notable success is Karuna Therapeutics, which was acquired by Bristol Myers Squibb for $14 billion in 2023.
What sets PureTech apart is their deep scientific expertise and hands-on approach to company building. The firm maintains a substantial internal team of scientists, clinicians, and drug development experts who work closely with portfolio companies throughout their development journey. This model has enabled them to create a pipeline of innovative therapies addressing significant unmet medical needs while generating substantial returns for investors.
“Creates and develops medicines for devastating diseases by combining cutting-edge science with innovative drug development approaches across multiple therapeutic areas.”
PureTech Health primarily invests at the Seed, Series A, Series B+ stages. This means they focus on companies that are building their initial product and finding product-market fit.
PureTech Health is headquartered in Boston, MA. Many of their portfolio companies are also based in this region, though they invest across geographies.
PureTech Health focuses on investments in Biotech, Digital Health. Their portfolio reflects deep expertise and networks within these sectors.